Recombinant Lassa Virus Expressing Green Fluorescent Protein as a Tool for High-Throughput Drug Screens and Neutralizing Antibody Assays
Lassa virus (LASV), a mammarenavirus, infects an estimated 100,000⁻300,000 individuals yearly in western Africa and frequently causes lethal disease. Currently, no LASV-specific antivirals or vaccines are commercially available for prevention or treatment of Lassa fever, the disease caused...
Main Authors: | Yíngyún Caì, Masaharu Iwasaki, Brett F. Beitzel, Shuīqìng Yú, Elena N. Postnikova, Beatrice Cubitt, Lisa Evans DeWald, Sheli R. Radoshitzky, Laura Bollinger, Peter B. Jahrling, Gustavo F. Palacios, Juan C. de la Torre, Jens H. Kuhn |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-11-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/10/11/655 |
Similar Items
-
A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene
by: Yingyun Cai, et al.
Published: (2020-02-01) -
A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region
by: Yingyun Cai, et al.
Published: (2020-03-01) -
Lassa Fever: Viral Replication, Disease Pathogenesis, and Host Immune Modulations
by: Hinh Ly
Published: (2020-06-01) -
Virus–Host Interactions Involved in Lassa Virus Entry and Genome Replication
by: María Eugenia Loureiro, et al.
Published: (2019-01-01) -
Pichinde Virus Infection of Outbred Hartley Guinea Pigs as a Surrogate Animal Model for Human Lassa Fever: Histopathological and Immunohistochemical Analyses
by: Wun-Ju Shieh, et al.
Published: (2020-07-01)